Targeting FcRn to Generate Antibody-Based Therapeutics
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The major histocompatibility complex (MHC) Class I-related receptor, FcRn, serves multiple roles ranging from the regulation of levels of IgG isotype antibodies and albumin throughout the body to delivery of antigen into antigen loading compartments in specialized antigen presenting cells. In parallel with studies directed towards understanding FcRn at the molecular and cellular levels, there has been an enormous expansion in the development of engineering strategies involving FcRn to modulate the dynamic behavior of antibodies, antigens and albumin. In the current review, we focus on a discussion of FcRn-targeted approaches that have resulted in the production of novel antibody-based platforms with considerable potential for use in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rab Proteins and the Compartmentalization of the Endosomal System
Wandinger-Ness, A., & Zerial, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022616 · Cited by 586
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 6×
“Consequently, they compete with endogenous antibodies for FcRn binding, driving such antibodies into degradative lysosomes [33].”
BackgroundSelf-citationCrystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Raghavan, M., Bonagura, V. R., Morrison, S. L., & Bjorkman, P. J. (1995) · Biochemistry · doi:10.1021/bi00045a005 · Cited by 317
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Self-citationSand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Reduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · cited 1×
“For example, the analysis of antibodies specific for Staphylococcal α-toxin with the ‘YTE’ half-life extending mutations (Met252 to Tyr, Ser254 to Thr, Thr256 to Glu that are all in proximity to the key residues of IgG that interact with FcRn (Figure 1B) [59]) during phase II clinical trials demonstrated half-lives ra…”
BackgroundThe FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211
Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., & Ward, E. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810796106 · Cited by 211
Self-citationCharge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408766112 · Cited by 202 · cited 1×
“This effect can be attributed to electrostatic interactions of regions of high density of positively charged residues in the complementarity determining regions (CDRs) located in the variable fragment (Fv) of the antibody [65,66].”
BackgroundWard, E. S., Martinez, C., Vaccaro, C., Zhou, J., Tang, Q., & Ober, R. J. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0735 · Cited by 193
Self-citationExtending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
Andersen, J. T., Dalhus, B., Viuff, D., Ravn, B. T., Gunnarsen, K. S., Plumridge, A., Bunting, K., Antunes, F., Williamson, R., Athwal, S., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549832 · Cited by 167
Claypool, S. M., Dickinson, B. L., Wagner, J. S., Johansen, F.-E., Venu, N., Borawski, J. A., Lencer, W. I., & Blumberg, R. S. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0832 · Cited by 139
Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules
Weflen, A. W., Baier, N., Tang, Q.-J., Van den Hof, M., Blumberg, R. S., Lencer, W. I., & Massol, R. H. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-04-0174 · Cited by 101
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98
(2018) · doi:10.1080/19420862.2017.1389355 · Cited by 80 · cited 1×
“This effect can be attributed to electrostatic interactions of regions of high density of positively charged residues in the complementarity determining regions (CDRs) located in the variable fragment (Fv) of the antibody [65,66].”
BackgroundAnalyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery
Gan, Z., Ram, S., Vaccaro, C., Ober, R. J., & Ward, E. S. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00887.x · Cited by 76
Self-citationUsing multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway
Gan, Z., Ram, S., Ober, R. J., & Ward, E. S. (2013) · Journal of Cell Science · doi:10.1242/jcs.116327 · Cited by 38 · cited 6×
“Pfeffer SR (2017) Rab GTPases: master regulators that establish the secretory and endocytic pathways.”
BackgroundSelf-citation
Cited by
B Cell Responses: Cell Interaction Dynamics and Decisions
Cyster, J. G., & Allen, C. D. C. (2019) · Cell · doi:10.1016/j.cell.2019.03.016 · Cited by 971
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
Brinkhaus, M., Pannecoucke, E., van der Kooi, E. J., Bentlage, A. E. H., Derksen, N. I. L., Andries, J., Balbino, B., Sips, M., Ulrichts, P., Verheesen, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33764-1 · Cited by 51
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Ma, G., Crowley, A. R., Heyndrickx, L., Rogiers, I., Parthoens, E., Van Santbergen, J., Ober, R. J., Bobkov, V., de Haard, H., Ulrichts, P., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176166 · Cited by 28
Self-citationV Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor
Rossini, S., Noé, R., Daventure, V., Lecerf, M., Justesen, S., & Dimitrov, J. D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000732 · Cited by 14
Metadata
- Authors
- Ward, E. S., & Ober, R. J.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 39
- Issue
- 10
- Pages
- 892-904
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2888528653
- Cited by
- 108
- References
- 22
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.